Patents by Inventor Jonathan David Roth
Jonathan David Roth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230115655Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.Type: ApplicationFiled: October 25, 2022Publication date: April 13, 2023Inventors: Mary ERICKSON, David C. LITZINGER, Soumitra S. GHOSH, Zijian GUO, Jonathan David ROTH
-
Patent number: 11535659Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.Type: GrantFiled: January 24, 2020Date of Patent: December 27, 2022Assignee: Amryt Pharmaceuticals Inc.Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Jonathan David Roth
-
Publication number: 20200362006Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.Type: ApplicationFiled: January 24, 2020Publication date: November 19, 2020Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Jonathan David Roth
-
Publication number: 20160137709Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.Type: ApplicationFiled: July 15, 2015Publication date: May 19, 2016Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Jonathan David Roth
-
Publication number: 20150231204Abstract: The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.Type: ApplicationFiled: November 12, 2014Publication date: August 20, 2015Inventors: Odile Esther LEVY, Carolyn M. Jodka, Soumitra S. Ghosh, David G. Parkes, Richard A. Pittner, Lawrence J. D'Souza, John S. Ahn, Kathryn S. Prickett, Jonathan David Roth, Sean H. Adams
-
Patent number: 8906849Abstract: The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.Type: GrantFiled: April 8, 2013Date of Patent: December 9, 2014Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Odile Esther Levy, Carolyn M. Jodka, Soumitra S. Ghosh, David G. Parkes, Richard A. Pittner, Lawrence J. D'Souza, John S. Ahn, Kathryn S. Prickett, Jonathan David Roth, Sean H. Adams
-
Publication number: 20140256621Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.Type: ApplicationFiled: July 3, 2012Publication date: September 11, 2014Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Caroline Ekbland, Jonathan David Roth
-
Patent number: 8748375Abstract: Methods for affecting body composition include the use of amylin agonists, such as pramlintide or davalintide. Total body weight may be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased.Type: GrantFiled: March 17, 2010Date of Patent: June 10, 2014Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Christine M. Mack, Jonathan David Roth
-
Publication number: 20140066368Abstract: Methods for affecting body composition include the use of amylin or amylin agonist(s). Total body weight be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased.Type: ApplicationFiled: August 20, 2013Publication date: March 6, 2014Applicants: AstraZeneca Pharmaceuticals, LP, Amylin Pharmaceuticals, LLCInventors: Christine Marie Mack, Jonathan David Roth
-
Publication number: 20130303442Abstract: The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.Type: ApplicationFiled: April 8, 2013Publication date: November 14, 2013Inventors: Odile Esther LEVY, Carolyn M. Jodka, Soumitra S. Ghosh, David G. Parkes, Richard A. Pittner, Lawrence j. D'souza, John S. Ahn, Kathryn S. Prickett, Jonathan David Roth, Sean H. Adams
-
Publication number: 20130274182Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.Type: ApplicationFiled: March 28, 2013Publication date: October 17, 2013Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Jonathan David Roth
-
Patent number: 8426361Abstract: The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.Type: GrantFiled: December 17, 2009Date of Patent: April 23, 2013Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Odile Esther Levy, Carolyn M. Jodka, Soumitra S. Ghosh, David G. Parkes, Richard A. Pittner, Lawrence J. D'Souza, John S. Ahn, Kathryn S. Prickett, Jonathan David Roth, Sean H. Adams
-
Publication number: 20120071401Abstract: Provided herein are methods to treat estrogen deficiency in mammals by administering amylin agonist compounds. Also provided herein are methods to treat obesity and overweight in estrogen-deficient mammals; methods to reduce or maintain body weight and/or body fat in estrogen-deficient mammals; and methods to increase Bdnf levels in mammals by administering effective amounts of amylin agonist compounds. The estrogen deficiency may be caused by menopause, perimenopause, post-menopause, ovarian dysfunction, an overectomy, a hysterectomy, and the like. The amylin agonist compounds may be any known in the art or described herein, such as pramlintide, davalintide, or SEQ ID NO: 142.Type: ApplicationFiled: April 9, 2010Publication date: March 22, 2012Applicant: Amylin Pharamaceuticals, Inc.Inventors: Jonathan David Roth, James L. Trevaskis, David G. Parkes
-
Publication number: 20120053118Abstract: Methods for affecting body composition include the use of amylin agonists, such as pramlintide or davalintide. Total body weight may be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased.Type: ApplicationFiled: March 17, 2010Publication date: March 1, 2012Applicant: AMYLIN PHARMACEUTICALS, INC.Inventors: Christine M. Mack, Jonathan David Roth
-
Publication number: 20100323955Abstract: Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain.Type: ApplicationFiled: November 14, 2007Publication date: December 23, 2010Applicant: AMYLIN PHARMACEUTICALS, INC.Inventors: Jonathan David Roth, Alain D. Baron, Christen Anderson
-
Patent number: 7723471Abstract: The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.Type: GrantFiled: December 12, 2005Date of Patent: May 25, 2010Assignee: Amylin Pharmaceuticals, Inc.Inventors: Odile Esther Levy, Carolyn M. Jodka, Soumitra S. Ghosh, David G. Parkes, Richard A. Pittner, Lawrence J. D'Souza, John S. Ahn, Kathryn S. Prickett, Jonathan David Roth, Sean H. Adams
-
Publication number: 20100099619Abstract: The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.Type: ApplicationFiled: December 17, 2009Publication date: April 22, 2010Applicant: AMYLIN PHARMACEUTICALS, INC.Inventors: Odile Esther Levy, Carolyn M. Jodka, Soumitra S. Ghosh, David G. Parkes, Richard A. Pittner, Lawrence J. D'Souza, John S. Ahn, Kathryn S. Prickett, Jonathan David Roth, Sean H. Adams
-
Publication number: 20080176804Abstract: Methods for affecting body composition include the use of amylin or amylin agonist(s). Total body weight may be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased.Type: ApplicationFiled: March 25, 2008Publication date: July 24, 2008Applicant: Amylin Pharmaceuticals, Inc.Inventors: Christine Marie Mack, Jonathan David Roth
-
Patent number: 7399744Abstract: Methods for affecting body composition include the use of amylin or amylin agonist(s). Total body weight may be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased.Type: GrantFiled: May 20, 2004Date of Patent: July 15, 2008Assignee: Amylin Pharmaceuticals, Inc.Inventors: Christine Marie Mack, Jonathan David Roth